Recently Featured

IXCHIQ Chikungunya Vaccine: Updated Restrictions Following Safety Review

February 18, 2026
Following a comprehensive safety review, the IXCHIQ Chikungunya vaccine has undergone significant changes in its usage guidelines. The Commission on Human Medicines (CHM) has recommended that the vaccine is no longer indicated for adults over the age of 60. Additionally, it is now contraindicated for individuals with pre-existing conditions such as hypertension, cardiovascular disease, diabetes…

Thx Pharma and Biocodex sign rare disease licensing deal

February 17, 2026
Biocodex has secured the licensing rights to Thx Pharma’s Batten-1 and TX01 in a significant agreement valued at up to €173 million. This deal underscores the growing interest in rare diseases, particularly in the context of innovative therapies that address unmet medical needs. The financial commitment reflects Biocodex’s strategic focus on expanding its portfolio in…

FDA Releases Condition-Specific Meeting Reports to Enhance Patient Experience Data

February 17, 2026
The FDA has made available a series of condition-specific meeting reports and related resources aimed at enriching the understanding of patient experiences in the pharmaceutical landscape. These reports are designed to serve a diverse audience, including patient advocates, researchers, and drug developers, by providing insights into the nuanced needs and preferences of patients across various…

Confidence in Safety of Certain Vaccines is Dropping

February 17, 2026
Recent surveys indicate a significant decline in public confidence regarding the safety of specific vaccines, particularly those developed for COVID-19 and seasonal influenza. This trend has emerged as a critical concern for healthcare professionals and regulatory bodies alike, as vaccine uptake is essential for maintaining public health and controlling outbreaks. The erosion of trust in…

Ongoing Cases